Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $276.44, for a total transaction of $55,288.00. Following the sale, the director now owns 8,080 shares in the company, valued at approximately $2,233,635.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Teleflex Incorporated (NYSE TFX) traded down $6.32 during trading on Friday, hitting $272.36. 194,501 shares of the stock traded hands, compared to its average volume of 265,123. The company has a market capitalization of $12,270.00, a PE ratio of 49.16, a P/E/G ratio of 2.05 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. Teleflex Incorporated has a 52-week low of $165.95 and a 52-week high of $288.78.
Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.11. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The firm had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. During the same quarter last year, the business posted $1.80 earnings per share. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. sell-side analysts expect that Teleflex Incorporated will post 8.36 earnings per share for the current fiscal year.
TFX has been the topic of several recent analyst reports. Morgan Stanley lifted their price objective on shares of Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Jefferies Group lifted their price objective on shares of Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Deutsche Bank cut shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price objective on the stock. in a research report on Tuesday, November 14th. Leerink Swann reiterated a “buy” rating and set a $321.00 price objective (up previously from $307.00) on shares of Teleflex in a research report on Tuesday. Finally, Stephens reiterated a “buy” rating and set a $300.00 price objective on shares of Teleflex in a research report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $283.89.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/02/stephen-k-m-d-klasko-sells-200-shares-of-teleflex-incorporated-tfx-stock.html.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.